HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,279,890 | +2.3% | 112,039 | -3.4% | 0.04% | +7.7% |
| Q2 2023 | $4,182,028 | -9.7% | 115,942 | -4.4% | 0.04% | -15.2% |
| Q1 2023 | $4,630,881 | +89437.5% | 121,259 | +33.4% | 0.05% | -41.0% |
| Q4 2022 | $5,172 | -99.9% | 90,902 | -8.3% | 0.08% | +23.8% |
| Q3 2022 | $3,918,000 | -11.0% | 99,089 | -0.9% | 0.06% | -10.0% |
| Q2 2022 | $4,402,000 | +10.6% | 100,039 | +0.2% | 0.07% | +29.6% |
| Q1 2022 | $3,980,000 | -2.5% | 99,811 | -1.7% | 0.05% | +8.0% |
| Q4 2021 | $4,081,000 | -4.7% | 101,496 | -3.6% | 0.05% | -5.7% |
| Q3 2021 | $4,283,000 | -5.4% | 105,290 | +5.6% | 0.05% | 0.0% |
| Q2 2021 | $4,529,000 | +14.3% | 99,743 | +5.0% | 0.05% | +8.2% |
| Q1 2021 | $3,961,000 | -9.1% | 95,000 | -6.9% | 0.05% | -10.9% |
| Q4 2020 | $4,358,000 | – | 102,033 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |